UPDATE ON INVESTMENT

BioPharma Credit PLC

22 July 2024

 

22 July 2024

BIOPHARMA CREDIT PLC

UPDATE ON INVESTMENT

BioPharma Credit PLC (LSE: BPCR) notes the update on the UK CMA (Competition and Markets Authority) website made on 19 July 2024 regarding the CMA's clearance of the proposed acquisition of LumiraDx by Roche. The updated website can be found in its entirety at: UK CMA Roche / LumiraDx merger inquiry.

With the CMA's clearance of the acquisition, we understand from LumiraDx that they are working with Roche towards finalizing the acquisition closing. We await further confirmation as to the status of the transaction and the satisfaction of all conditions to acquisition closing, including regulatory and antitrust review. At this time, Pharmakon Advisors, LP cannot further comment beyond what has been made public by the CMA and the companies involved in the transaction.

Pharmakon Advisors, LP is continuing to actively monitor the situation and will provide any updates in due course.

Enquiries

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

[phone]

[e-mail]

Notes to Editors

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

END